基本信息
浏览量:7
职业迁徙
个人简介
We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma. These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on adoptive transfer of tumor and viral antigen-specific T cells.
Our current clinical trials include phase I and II studies of immunotherapy for: patients with metastatic malignancies expressing CEA, pancreatic cancer, colorectal cancer, breast cancer, and ovarian cancer, and leukemias following HSCT. My clinical area of expertise is in gastrointestinal oncology, in particular, the treatment of hepatic malignancies, and malignant melanoma.
研究兴趣
论文共 281 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Neal Shiv Chawla,Samantha Jeffrey,Nadezhda Omelchenko, Rheanna Carter, Anmol Dia Agarwal, Ishrat Buhyian,William H. Isacoff,Michael Morse,William Swaney,Sant P. Chawla, Frederick L. Hall,Erlinda Maria Gordon
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)
openalex(2023)
crossref(2023)
crossref(2023)
crossref(2023)
openalex(2023)
crossref(2023)
Erika J. Crosby,Chaitanya R. Acharya, Anthony-Fayez Haddad,Christopher A. Rabiola,Gangjun Lei,Jun-Ping Wei,Xiao-Yi Yang,Tao Wang,Cong-Xiao Liu,Kay U. Wagner,William J. Muller,Lewis A. Chodosh,Gloria Broadwater,Terry Hyslop,Jonathan H. Shepherd,Daniel P. Hollern,Xiaping He,Charles M. Perou,Shengjie Chai, Benjamin K. Ashby,Benjamin G. Vincent,Joshua C. Snyder,Jeremy Force,Michael A. Morse,Herbert K. Lyerly,Zachary C. Hartman
openalex(2023)
crossref(2023)
crossref(2023)
加载更多
作者统计
#Papers: 282
#Citation: 10362
H-Index: 47
G-Index: 96
Sociability: 7
Diversity: 3
Activity: 70
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn